Literature DB >> 19660355

Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.

Apurva Patel1, Masaki Anraku, Gail E Darling, Frances A Shepherd, Andrew F Pierre, Thomas K Waddell, Shaf Keshavjee, Marc de Perrot.   

Abstract

OBJECTIVE: The rate of venous thromboembolism in patients undergoing multimodality therapy for lung malignancy and the impact of preoperative venous thromboembolism on postoperative outcome have not been analyzed systematically.
METHODS: We performed a retrospective review of all patients undergoing induction therapy before lung resection for non-small cell lung cancer and malignant pleural mesothelioma at the University Health Network between January 1996 and December 2007.
RESULTS: Venous thromboembolism developed in 23 (12.3%) of 186 patients undergoing induction therapy. The venous thromboembolism was diagnosed during induction therapy in 11 patients. The proportion of pulmonary embolism was higher during induction therapy (9/11 patients), whereas deep venous thromboses were observed predominantly postoperatively (7/12 patients) (P = .02). The risk of postoperative complications or death was not increased in patients undergoing surgery despite a preoperative diagnosis of venous thromboembolism. However, the risk of postoperative pulmonary embolism was higher in patients undergoing surgery without insertion of an inferior vena cava filter (1/2 patients vs 0/7 after insertion of an inferior vena cava filter, P = .047). The overall survival was similar between patients with or without venous thromboembolism complications.
CONCLUSION: This study demonstrates that venous thromboembolism events in patients undergoing multimodality therapy for lung malignancies is high and deserves careful consideration. Patients with a venous thromboembolism diagnosis during induction therapy may potentially benefit from a temporary inferior vena cava filter before surgery to limit the risk of recurrent pulmonary embolism. A preoperative diagnosis of venous thromboembolism, however, does not affect early and late outcomes after surgery and should not be viewed as a negative prognostic marker.

Entities:  

Mesh:

Year:  2009        PMID: 19660355     DOI: 10.1016/j.jtcvs.2009.02.028

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Technical pitfalls and solutions in extrapleural pneumonectomy.

Authors:  Stephane Collaud; Marc de Perrot
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer.

Authors:  Sai Yendamuri; Adrienne Groman; Austin Miller; Todd Demmy; Mark Hennon; Elisabeth Dexter; Anthony Picone; Chukwumere Nwogu; Grace K Dy
Journal:  Eur J Cardiothorac Surg       Date:  2018-03-01       Impact factor: 4.191

3.  What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?

Authors:  Andrea Billè; Lawrence Okiror; Wolfram Karenovics; John Pilling; Loïc Lang-Lazdunski
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-23

Review 4.  Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.

Authors:  Yupeng Li; Yu Shang; Wenwen Wang; Shangwei Ning; Hong Chen
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.